LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. The company’s lead development program is with catumaxomab, a clinically validated bispecific antibody which was the first approved T-cell engager, and its associated Triomab technology platform. LintonPharm, in collaboration with Lindis Biotech, is also developing a next generation bispecific antibody platform known as Fleximab which aims to provide better CMC developability and less immunogenicity. The LintonPharm pipeline includes several treatments in development for blood cancer and solid tumors that use the Triomab and Fleximab platforms. For more information, please visit www.lintonpharm.com.
Company Details
- Employees
- 5
- Founded
- 2017
- Address
- 黄埔区南翔三路, 广州市,广东省 510000,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lintonpharm.com/
- Keywords
- Philipsburg.
- HQ
- 广州市, 广东省
Guangzhou Lintonpharm Co.,ltd. Questions
Guangzhou Lintonpharm Co.,Ltd.'s website is http://www.lintonpharm.com/
Guangzhou Lintonpharm Co.,Ltd.'s LinkedIn profile is https://cn.linkedin.com/company/%E5%B9%BF%E5%B7%9E%E5%87%8C%E8%85%BE%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Guangzhou Lintonpharm Co.,Ltd. has
5 employees.
View email and phone details for 5
employees at Guangzhou Lintonpharm Co.,Ltd..
Guangzhou Lintonpharm Co.,Ltd.'s industry is
Biotechnology Research
Guangzhou Lintonpharm Co.,Ltd.'s top competitors are
Wuxi Discovery Services,
Foresite Labs,
Issyzone Tech Co. Limited,
Vir Biotechnology, Inc.,
Bridgene Biosciences, Inc.,
Lynk Pharmaceuticals,
Brainever,
Gordian Biotechnology,
Emily Whitehead Foundation,
Ltz Therapeutics.
Guangzhou Lintonpharm Co.,Ltd.'s categories are Biotechnology Research
Guangzhou Lintonpharm Co.,Ltd.'s founding year is 2017
